

Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome

*Chowdhury MFK¹, Ghosh CK², Miah MSA³, Uddin MA⁴, Russell M⁵, Rashid MH⁶, Pal AK⁷, Mahabub-Uz-Zaman K⁸, Saha KP⁹, Miah MAR¹⁰

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disorder of the gastrointestinal tract with relapsing and remitting course. Recurrent abdominal pain and discomfort in association with abnormal defecation in the absence of structural abnormality of the gut is the key feature of irritable bowel syndrome (IBS). Faecal biomarker may be used a precise tool in the differentiation of IBD and IBS. The aim of this study was to measure faecal calprotectin (FC) in patients with IBD and IBS and compare between them. This was a cross-sectional study done in the department of Gastroenterology, BSMMU, Bangladesh from May 2017 to August 2018. IBD patients were diagnosed on the basis of compatible history, clinical examination, laboratory, radiological and endoscopic findings. IBS patients were selected by using the Rome IV criteria. Quantitative faecal calprotectin ELISA (BUHLMANN Quantum Blue) test was done and compared between IBD and IBS patients. In this study, ninety (90) patients were enrolled, 45 patients with IBD and 45 patients with IBS. Mean age of the IBD patients was 32.24±9.76 years and IBS patients was 33.80±9.70 years. There were 28(62.2%) male and 17(37.8%) female patients with IBD and 30(66.7%) male and 15(33.3%) female patients with IBS. We found faecal calprotectin (FC) level was 445.68±237.35µg/gm in IBD patients and 39.16±17.31µg/gm in IBS patients. There was a significant difference of faecal calprotectin level between IBD and IBS patients (p-value <0.001). The sensitivity and specificity of faecal calprotectin to differentiate IBD from IBS was 91.1% and 86.7% respectively. The test accuracy was 88.9%. Area under ROC was 0.959 (95% CI, 0.909 to 1.0). This study showed that faecal calprotectin appears to be clinically useful, non-invasive, rapid and reliable marker to differentiate IBD from IBS.

[Mymensingh Med J 2024 Oct; 33 (4): 1149-1156]

Key words: Inflammatory Bowel disease, Irritable bowel syndrome, Faecal calprotectin

Introduction

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD) are chronic idiopathic inflammatory disorders of the gastrointestinal tract with a typically relapsing and remitting course. Peak incidence of UC and CD occurs in second to fourth decade of life. Genetic susceptibility and a number of environmental factors such as smoking, drugs, diets and infectious gastroenteritis are related to IBD¹. Crohn's disease (CD) is a chronic inflammatory disorder that may involve any part of the alimentary tract from mouth to anus. It can involve all layers of intestine from mucosa to serosa. Patients usually present with diarrhoea, abdominal pain and weight loss. Common complications include stricture and fistula. Numerous extra intestinal manifestations also may occur². Ulcerative colitis (UC) is a chronic relapsing and remitting disease characterized by diffuse mucosal inflammation of the colon³. The exact etiology of UC is unknown however it is thought to be caused by inflammatory response to the gut contents in genetically predisposed individuals⁴. The cardinal symptoms of UC are rectal bleeding with passage of mucous and bloody diarrhoea.

1. *Dr Md Fazlul Karim Chowdhury, Assistant Professor, Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; E-mail: chanchal4234@gmail.com
2. Dr Chanchal Kumar Ghosh, Professor, Department of Gastroenterology, BSMMU, Dhaka
3. Dr Md Shah Alam Miah, Assistant Registrar, Sheikh Russel National Gastroenterology Institute and Hospital, Dhaka, Bangladesh
4. Dr Mohammad Azim Uddin, Junior Consultant (Surgery), Department of Surgery, MMCH, Mymensingh, Bangladesh
5. Dr Md Russell, Assistant Professor (Surgical Oncology), Department of Surgery, BSMMU, Dhaka, Bangladesh
6. Dr Mohammad Haroon Or Rashid, Phase B Resident, Department of Colorectal Surgery, BSMMU, Dhaka, Bangladesh
7. Dr Arun Kumar Pal, Assistant Professor, Department of Surgery, DMCH, Dhaka
8. Dr Khandkar Mahabub-Uz-Zaman, Assistant Registrar, Sheikh Russel National Gastroenterology Institute and Hospital, Dhaka, Bangladesh
9. Dr Krishna Pada Saha, Assistant Professor, Department of Colorectal Surgery, BSMMU, Dhaka, Bangladesh
10. Dr Md Abdur Rahim Miah, Professor, Department of Gastroenterology, BSMMU, Dhaka, Bangladesh
*for correspondence

In severe or extensive UC, acute complications such as severe bleeding, toxic megacolon and perforation may occur. Colorectal cancer is common in UC patients compared to the general population; risk factors include long duration of disease, extensive colonic involvement, severe inflammation and epithelial dysplasia and childhood-onset disease⁵. There is no single test which allows the diagnosis of IBD. Diagnosis of IBD and differentiation between CD and UC which can be made accurately in most patients based on the patient's history and physical examination, ileocolonoscopy examination, biopsy, double contrast barium enema examination and microbiology⁶. Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterized by altered bowel habit in association with abdominal discomfort and pain in the absence of detectable structural and biochemical abnormalities⁷. Visceral hypersensitivity, altered gastrointestinal motility, post infectious reactivity, brain-gut interactions, alteration of faecal microflora, bacterial overgrowth, food sensitivity, carbohydrate malabsorption and intestinal inflammation all have been implicated in the pathogenesis of IBS⁸. IBS is diagnosed on the basis of patient-reported symptoms after exclusion of biochemical and anatomical pathology since no reliable biomarker is present⁹. The use of recognized diagnostic criteria does allow for a certain degree of standardization in patient characteristics and Rome III is useful resources for this purpose¹⁰. Rome III criteria cannot exclude IBD before the diagnosis of IBS. Till date there are only few researches about Rome III criteria for diagnosing IBS which is the most commonly used criteria in the world. It has modest value to diagnose IBS. Recently, it showed that Rome IV criteria are much superior to the Rome III criteria, although the clinical relevance of this is uncertain¹¹. IBS is a chronic functional gastrointestinal disorder that affects about 23.0% of the population across the world. Patients who are seeking health care related to IBS are by far the largest subgroup seen in gastroenterology clinics in primary health care settings¹². In Bangladesh, its prevalence is reported at 20.6% in men and 27.7% in women¹³. Women present with IBS more commonly than men with a ratio of 2:1¹⁴. Though, this syndrome is not life threatening, it can significantly impair quality of life resulting in high health care costs¹⁵.

This economic burden adds to the importance of accurately diagnosing and managing IBS in both primary and secondary healthcare. Lower GI endoscopy was done in most of the patients presented with chronic diarrhoea. IBS is a chronic functional GI disorder. But, if IBD is missed then, several life threatening complications may occur such as, toxic megacolon, intestinal perforation, intestinal obstruction and colonic malignancy. Due to lack of simple clinical or laboratory mean, we do colonoscopy for all. Most of colonoscopic findings are negative, but we do it to ensure that IBD is not missed¹⁶. We routinely use the inflammatory marker, C-reactive protein (CRP), to track inflammation in our IBD patients, but in our experience, it lacks sufficient sensitivity to make the diagnosis¹⁷. In several conditions serum markers of intestinal inflammation can be raised. Faecal markers of inflammation in the absence of enteric infection would be more specific for IBD¹⁸. Usually faecal biomarkers provide a reliable and simple noninvasive means in the differentiation of IBD and IBS; calprotectin appears to represent the most accurate marker to differentiate between IBD and IBS¹⁹. Calprotectin may be used as precise markers for various reasons. Most of the proteins in neutrophils are calprotectin. Calprotectin in stool can be considered directly proportional to neutrophil migration to the gastrointestinal tract^{20,21}. It is difficult to distinguish IBD from IBS using symptoms and signs only. Most patients with IBS are evaluated by endoscopy and radiographic imaging to exclude a diagnosis of IBD as clinical differentiation remains challenging and may delay effective treatment. This not only exposes patients to the inherent risks associated with this procedure, but also increases their economic burden¹⁹. Endoscopic evaluation is often not comfortable but also expensive and has some significant risk such as perforation²². Radiological imaging also has drawbacks with observer variability and does not allow histological sampling²³. Therefore, in this situation a simple, rapid, non-invasive and inexpensive test in discriminating IBD from IBS is of great importance. Environmental and genetic factors are implicated in IBD pathogenesis. Several studies were done in western population regarding faecal calprotectin. But only limited data are available in Bangladesh in this regard. So, this cross-sectional observational study was done in Bangladeshi

population to see the value of faecal calprotectin level to differentiate IBD from IBS.

Methods

This was a cross-sectional study done in the department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh from May 2017 to August 2018. IBD patients were selected on the basis of compatible history, clinical examination, and laboratory, radiological and endoscopic findings^{2,24}. IBS patients were selected using the Rome IV criteria²⁵. A total of 45 IBD and 45 IBS patients were enrolled purposively aged 18-50 years. IBD and IBS patients diagnosed based on aforementioned criteria were enrolled. Patients with microscopic colitis, indeterminate colitis, infectious colitis, colorectal carcinoma, intestinal tuberculosis, intestinal lymphoma, colonic polyp, history of taking NSAIDs, pregnancy were excluded. IBS patients having alarm features such as anemia, fever, weight loss, melaena, family history of colon cancer, thyroid disease and Diabetes mellitus were excluded. Complete blood count, erythrocyte sedimentation rate (ESR), CRP, RBS, serum albumin, stool R/M/E, stool culture, celiac serology, thyroid function test, abdominal ultrasound and ileocolonoscopy was done. Barium follow through or enteroscopy was also done case by case basis where needed to confirm the diagnosis. Quantitative faecal calprotectin ELISA test was performed. The study was performed after taking ethical clearance from Institutional Review Board (IRB) of BSMMU.

Estimation of faecal calprotectin

For estimation of faecal calprotectin less than 1 gram of native stool was collected in plain tubes without any chemical or biological additives. Samples were stored in refrigerator at 2-8 degree Celsius. Quantitative measurement of faecal calprotectin was done in the department of microbiology, BSMMU. A cut off value ≥ 50 microgram/gram was considered positive as per manufacturer's guide.

Sample collection

For estimation of faecal calprotectin less than 1 gram of native stool was collected in plain tubes without any chemical or biological additives. Samples were stored in refrigerator at 2-8 degree Celsius. All patients were requested to provide a stool sample in a container supplied to them.

Test procedure

The procedure was introduced for the selective measurement of calprotectin antigen. A monoclonal antibody (mAb) being more accurate for calprotectin is attached onto the test membrane. Another monoclonal detection antibody conjugated to gold colloids is deposited onto the conjugate pad and secreted into the examination system after addition of the extracted diluted stool sample. The intensities of test lines are measured quantitatively by the BUHLMANN Quantum Blue Reader. The concentration of calprotectin is directly proportional to the color intensity in the test sample.

Statistical analysis

Numerical variables were presented as mean \pm SD. Categorical variables were expressed in percentage. A p-value ≤ 0.05 were considered statistically significant. Only age was normally distributed. All other numerical variables were non-normally distributed. During comparison of two independent numerical variables, student's t test and Mann Whitney U test were used for normally and non-normally distributed data respectively. Two set of categorical variables were tested using Chi-Square test. Sensitivity and specificity was calculated for each test by 95% confidence interval.

Ethical consideration

Before starting this study, the research protocol was submitted to the institutional review board (IRB) of BSMMU, Bangladesh and IRB clearance was obtained (Memo no BSMMU/2017/5617 Dated: 24-05-2017). All participants were informed about the objectives, methodology and purpose of the study in easily understandable way. Verbal and written consents were obtained from all participants without any influences prior to sample collection.

Results

A total of 90 patients were enrolled, among them 45 were IBD patients and 45 were IBS patients. Mean age of the IBD patients was 32.24 ± 9.76 years and IBS patients was 33.80 ± 9.70 years. Twenty eight (62.2%) male and 17(37.8%) female patients with IBD and 30(66.7%) male and 15(33.3%) female patients were with IBS. Demographic variables are shown in Table I. Hemoglobin level was significantly lower in IBD patients than IBS patients ($p \leq 0.001$). ESR and CRP were significantly higher in IBD group (Table I). Faecal calprotectin level was

Original Contribution

445.68±237.35µg/gm in IBD patients and 39.16±17.31µg/gm in IBS patients (p<0.001) shown in Table II. Distribution of the patients according to level of faecal calprotectin at a cut off value 50µg/gm of stool is shown in Table III. No significant difference of faecal calprotectin was found between ulcerative colitis (UC) and Crohn’s disease (CD) (Table IV). The sensitivity and specificity of faecal calprotectin to distinguish between IBD and IBS using a cut-off value

50µg/gm was 91.1% and 86.7% respectively, with a negative predictive value 90.7% and positive predictive value 87.2%. The test accuracy was 88.9%. Area under ROC was 0.959 (95% CI, 0.909 to 1.0) which is close to 1. It indicates that classifier was very good and difference between the test results of the IBD and IBS was highly significant (p-value <0.001); shown in Table V and Figure 1.

Table I: Demographic and biochemical factors (n=90)

Variables	IBD group (n=45)	IBS group (n=45)	p value
	Mean±SD	Mean±SD	
Age in years	32.2 ± 9.8	33.8 ± 9.7	0.450 ^a
<i>Gender [n (%)]</i>			
Male	28 (62.2)	30 (66.7)	0.660 ^b
Female	17 (37.8)	15 (33.3)	
Hb (gm/dl)	9.9 ± 0.9	13.4 ± 1.1	<0.001 ^c
ESR (mm in 1 st hour)	47.5 ± 16.8	15.9 ± 9.9	<0.001 ^c
CRP(mg/L)	21.1 ± 11.8	4.2 ± 1.1	<0.001 ^c

a=Students t-test, b= Chi-square test, c= Mann-Whitney U test.

Table II: Faecal Calprotectin level in IBD and IBS patients (N=90)

Parameter	Groups		p value (Mann-Whitney U test)
	IBD (n=45)	IBS (n=45)	
Faecal calprotectin (µg/gm) [Mean±SD]	445.68±237.35	39.16±17.31	<0.001

Table III: Distribution of the patients according to level of faecal calprotectin level at a cut off value 50µg/gm of stool (n=90)

Faecal Calprotectin (µg/gm of stool)	Groups		Total	p value (Chi-square test)
	IBD	IBS		
	n (%)	n (%)		
≥50	41 (91.1)	06 (13.3)	47 (52.2)	<0.001
<50	04 (08.9)	39 (86.7)	43 (47.8)	
Total	45 (100.0)	45 (100.0)	90 (100.0)	

Table IV: Faecal Calprotectin level in CD and UC patients (n=45)

Parameter	Groups		p value (Mann-Whitney U test)
	CD (n=23)	UC(n=22)	
Faecal calprotectin (µg/gm) [Mean±SD]	413.91±230.24	478.90±245.43	0.358


Table V: Performance of diagnostic test of faecal calprotectin at a cut off value 50µg/gm

Performance of diagnostic test	Percent (%)	95% CI	
		Min	Max
Sensitivity	91.1	81.7	96.6
Specificity	86.7	77.3	92.2
Positive predictive value	87.2	78.2	92.5
Negative predictive value	90.7	80.8	96.5
Accuracy	88.9	79.5	94.4

Performance of diagnostic test of faecal calprotectin at a cut-off value 50µg/gm to differentiate IBD from IBS.

ROC (Receiver operator characteristic) curve

The curve was generated by plotting the relationship of true positive versus false positive rate as the threshold value for classifying an item as 0 or is increased from 0 to 1. The figure shows AUC score of 0.959, which is close to 1. It indicates that classifier was very good and difference between the test results of the IBD and IBS were highly significant (p-value <0.001).



Diagonal segments are produced by ties.

Figure 1: Area under ROC curve showing 0.959 with 95% CI, (0.909-1.000), (p-value <0.001)

Discussion

The mean age of the patients with IBD was 32.24±9.76 years and IBS patients was 33.80±9.70 years. Mehrjardi et al.²⁶ conducted a similar study and found the mean age of the IBD patients was 35.4±8.6 years and the mean age of the IBS patients was 32.3±6.8 years. The mean age of the patients of this study was close to this study. Considering gender distribution, among the

IBD patients 28(62.2%) were male and 17(37.8%) were female. On the other hand 30(66.7%) were male and 15(33.3%) were female in IBS patients. Male patients were predominant in both groups in our study. Mehrjardi et al.²⁶ showed majority of patients in both groups were female. This dissimilarity may be due to easy health care access for male is in our country. For estimation of faecal calprotectin we used the BUHLMANN Quantum

Blue Reader in this study. Same method was used by other authors like Sharbatdaran M et al.²⁷, Dhaliwal et al.²⁸, Chang et al.²⁹ and Kotze et al.³⁰. In this study, low hemoglobin, high ESR and CRP was found in IBD patients. On the other hand, normal hemoglobin and low ESR and CRP was found in IBS patients ($p < 0.001$). This finding was similar as studied by said et al.³¹, whereas no difference of ESR was found in two groups of patients as studied by Chang et al.³⁰. In this study, we found mean faecal calprotectin level was $445.68 \pm 237.35 \mu\text{g/gm}$ in IBD patients and $39.16 \pm 17.31 \mu\text{g/gm}$ in IBS patients. Significant difference of faecal calprotectin level between IBD and IBS patients was found ($p\text{-value} < 0.001$). Faecal calprotectin at a cut-off value $50 \mu\text{g/gm}$ showed sensitivity 91.1%, specificity 86.7% to differentiate IBD from IBS, PPV 87.2%, NPV 90.7% and test accuracy was 88.9%. Consistent result was found in another study done by Kotze et al.³⁰ in 2015. They found faecal calprotectin level in Crohn's disease was $405 \mu\text{g/gm}$ and in Ulcerative colitis was $457 \mu\text{g/gm}$ and in IBS patients was $50.5 \mu\text{g/gm}$. A significant difference of faecal calprotectin level was found between IBD and IBS patients with p value < 0.001 . Another study done by Dhaliwal et al.²⁸ in 2015 had shown that faecal calprotectin level was $674.0 \pm 480.0 \mu\text{g/gm}$ in active IBD patients and $34.0 \pm 69 \mu\text{g/gm}$ in IBS patients. Sensitivity and specificity of faecal calprotectin to differentiate IBD from IBS using a cut off value of $50 \mu\text{g/gm}$ was 88.0% and 78.0% respectively. A study in Tiawan by Chang et al.²⁹ in 2014 found mean faecal calprotectin level in IBD patients was $694.8 \pm 685.0 \mu\text{g/gm}$ and $85.8 \pm 136.1 \mu\text{g/gm}$ in IBS patients ($p < 0.001$). In comparison of our study, close results were seen regarding difference of faecal calprotectin level in IBD and IBS patients in previous two studies. But faecal calprotectin level was higher in IBD patients in comparison to this study. This could be explained by most patients in this study were previously diagnosed and most of them getting treatment for long time. But, in above mentioned studies all patients were newly diagnosed and faecal calprotectin level was measured before treatment started. Langhorst et al.³³ and Xiang et al.³³ showed significant difference of faecal calprotectin between IBD in relapse and IBD in remission. There were 6 patients with elevated faecal calprotectin level in IBS which may be due to subtle inflammation or

post- infectious IBS as explained by David et al.³⁴ where as patients of IBD had $< 50 \mu\text{g/gm}$ of faecal calprotectin level which may be due to IBD in remission as shown by Said et al.³¹, Erik et al.³⁵ and Dhaliwal et al.²⁸. In this study, faecal calprotectin level was significantly higher in IBD patients in comparison to IBS patient, which is similar that of other studies conducted by Tibble et al.³⁶, Antonio et al.³⁷ and Schoepfer et al.³⁹. Schoepfer et al.³⁸ measured faecal calprotectin by using another kit and their findings were similar with our study results. C-reactive protein and ESR are commonly used inflammatory markers used by clinicians to discriminate organic gastrointestinal diseases from functional GI disorder. Sensitivity and specificity of ESR and CRP is much lower than faecal calprotectin. Faecal calprotectin is more superior to CRP and ESR to differentiate IBD from IBS³⁹.

Conclusion

In conclusion, based on this study findings and previous study results, estimation of faecal calprotectin is a simple, rapid, precise and non-invasive test to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS).

Limitation

Healthy controls were not taken in the study population. All patients were recruited in this study from a single tertiary level hospital which does not reflect the whole country.

Clinical significance

Faecal calprotectin can be used as a screening tool before selection of patients for colonoscopy in adjunct with other clinical examinations to differentiate IBD from IBS.

References

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis and therapeutic opportunities. *Inflamm Bowel Dis.* 2006;12(Suppl 1):S3-9.
2. Sands BE, Siegel CA. Crohn's Disease. In: Feldman M, Friedman LS, Brandt Lawrence J. eds. *Sleisenger and Fordtran's Gastrointestinal and Liver disease.* 10th ed. Elsevier Saunders. 2016. p.1990-2021.
3. Langan RC, Gotsch PB, Krafczyk MA, Skillings DD. Ulcerative colitis: diagnosis and

- treatment. *American Family Physician*. 2007; 6(9):1323-30.
4. Talley NJ, Fodor AA. Bugs, stool and the irritable bowel syndrome: too much is as bad as too little? *Gastroenterology*. 2011;141(5): 1555-9.
 5. Danese S, Fiocchi C. Ulcerative Colitis. *N Engl J Med*. 2011;365(18):1713-25.
 6. Xavier Bossuyt. Serologic Markers in Inflammatory Bowel Disease. *Clinical Chemistry*. 2006. p.171-81.
 7. Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology*. 2006;130(5):1377-90.
 8. Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. *Clinics in Colon and Rectal Surgery*. 2012;25(1):46-52.
 9. Miller LE. Study design considerations for irritable bowel syndrome clinical trials. *Ann Gastroenterol*. 2014;27(4):338-45.
 10. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional Bowel Disorders. *Gastroenterology*. 2006;130:1480-91.
 11. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. *Gastroenterology*. 2013;145(6):1262-70.
 12. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment and evidence-based medicine. *World Journal of Gastroenterology*. 2014;20(22):6759-73.
 13. Masud MA, Hasan M, Khan AA. Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern and health care seeking behavior. *The American Journal of Gastroenterology*. 2001; 96(5):1547-52.
 14. Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N. Systematic review on the management of irritable bowel syndrome in North America. *The American Journal of Gastroenterology*. 2002;97(11):S7-26.
 15. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, Verrier P, Poitras P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. *Gastroenterology*. 2002;122(7):1771-7.
 16. Banerjee A, Srinivas M, Eyre R, Ellis R, Waugh N, Bardhan KD, Basumani P. Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice. *Frontline Gastroenterology*. 2015;6(1):20-6.
 17. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technol Assess*. 2013;17(55):1-211.
 18. Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: What is the role of biomarkers? *Gut*. 2005; 54(3):321-2.
 19. Schröder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. *Alimentary Pharmacology & Therapeutics*. 2007;26(7): 1035-42.
 20. Vermeire S, VanAssche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? *Gut*. 2006;55(3):426-31.
 21. Røseth AG, Fagerhol MK, Aadland E, Schjønshy H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. *Scandinavian Journal of Gastroenterology*. 1992;27(9):793-8.
 22. Blotière PO, Weill A, Ricordeau P, Alla F, Allemand H. Perforations and haemorrhages after colonoscopy in 2010: a study based on comprehensive French health insurance data (SNIIRAM). *Clinics and Research in Hepatology and Gastroenterology*. 2014; 38(1):112-7.
 23. Jensen MD, Ormstrup T, Vagn-Hansen C, Østergaard L, Rafaelsen SR. Interobserver and intermodality agreement for detection of small bowel Crohn's disease with MR enterography and CT enterography. *Inflamm Bowel Dis*. 2011;17(5):1081-8.
 24. Osterman MT, Lichtensten GR. Ulcerative Colitis. In: Feldman LS, Brandt LJ. eds. *Sleisenger and Fordtran's Gastrointestinal and Liver disease*. 10th ed. India: Elsevier Saunders. 2016. p.2023-61.

25. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. *Gastroenterology*. 2016;150(6):1393-1407.
26. Mehrjardi A, Saber-Afsharian M, Mirskandari M, Ebrahimi-Daryani N, Faghihi A, Iranikhah T. Comparison of fecal calprotectin level in inflammatory bowel disease and irritable bowel syndrome. *Govaresh*. 2010;14(4):275-8.
27. Sharbatdaran M, Holaku A, Kashifard M, Bijani A, Firozjahi A, Hosseini A, Siadati S. Fecal calprotectin Level in patients with IBD and non-inflammatory disease of colon: a study in Babol, Northern Iran. *Caspian Journal of Internal Medicine*. 2018;9(1):62-4.
28. Dhaliwal A, Zeino Z, Tomkins C, Cheung M, Nwokolo C, Smith S, Harmston C, Arasaradnam RP. Utility of faecalcalprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? *Frontline Gastroenterol*. 2015;6(1):14-9.
29. Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. *Mol Med Rep*. 2014;10(1):522-6.
30. Kotze LMDS, Nisihara RM, Marion SB, Cavassani MF, Kotze PG. Fecal Calprotectin: levels for the etiological diagnosis in Brazilian patients with gastrointestinal symptoms. *Arquivos de gastroenterologia*. 2015;52(1):50-4.
31. Said HE, Monis AA, El-Aziz MM, El-Sayed EY, Shabana SS, El-Sadek ASA, Dogra KS, Kohli RK, Sood SK, Dobhal PK, Sharma S. The diagnostic value of faecal calprotectin in differentiating inflammatory bowel diseases (IBD) from irritable bowel syndrome (IBS). *Rep Opinion*. 2011;3:1-8.
32. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP and clinical indices. *Am J Gastroenterol*. 2008;103(1):162-9.
33. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. *World J Gastroenterol*. 2008;14(1):53-7.
34. David LE, Surdea-Blaga T, Dumitrascu DL. Semi-quantitative fecal calprotectin test in post infectious and non-post-infectious irritable bowel syndrome: cross-sectional study. *Sao Paulo Med J*. 2015;133(4):343-9.
35. Mooiweer E, Severs M, Schipper MEI, Fidler HH, Siersema PD, Laheij RJF, Oldenburg B. Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission. *Journal of Crohn's and Colitis*. 2015;9(1):50-5.
36. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. *Gut*. 2000;47(4):506-13.
37. Carroccio A, Iacono G, Cottone M, Prima LD, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Fede GD, Rini GB, Notarbartolo A, Averna MR. Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children. *Clinical Chemistry*. 2003;49(6):861-7.
38. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP and IBD antibodies. *Inflamm Bowel Dis*. 2008;14(1):32-9.
39. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. *World Journal of Gastroenterology*. 2001;7(4):460-5.